Nexalin Advances FDA Alzheimer’s Strategy Following Leadership Meetings in the U.S. and China
Nexalin Technology, Inc. (NXL) has advanced its FDA application strategy for Alzheimer’s treatment following key meetings in the U.S. and China. The company is finalizing its clinical trial design based on FDA guidance and plans to submit an amended Q-Submission in Q2 2026. The meetings involved academic and clinical experts to shape the trial's endpoints and regulatory pathway.
Topics: Alzheimer's Disease Clinical Trials FDA Approval Neurostimulation Regulatory Strategy